DQS: The New Evolution of dd-cfDNA Testing and Noninvasive Rejection Monitoring, Presented by Natera
.png?sfvrsn=2469a18_1)
In this episode of the ISHLT Voices podcast, hosted by Natera, you’ll hear the following transplant cardiologists explore the evolving landscape of post-heart transplant care, zeroing in on the transformative shift from traditional, invasive biopsies to cutting-edge noninvasive molecular diagnostics—particularly cell-free DNA technologies:
Brent Lampert, DO
Ajith P. Nair, MD, FACC, FAHA
Drs. Lampert and Nair discuss the clinical promise of tools like Natera’s Prospera Heart with Donor Quantity Score (DQS), which not only offer heightened accuracy and earlier detection of graft injury and rejection, but also may empower clinicians to strike a vital balance: preventing rejection without over-immunosuppression.
Real world insights, compelling case examples, and candid discussions about the challenges of biopsy-based monitoring—and how new technology is reshaping decisions, outcomes, and patient peace of mind—make this a must-listen for anyone intrigued by the future of transplantation medicine.
The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.
This episode was created for ISHLT Voices and supported by Natera.
